NASDAQ
28.08.26 | 22:00
9,180 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.07. | Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4 | 1 | Seeking Alpha | ||
| 30.07. | Guggenheim senkt Kursziel für Phathom Pharmaceuticals nach Prognosekorrektur | 3 | Investing.com Deutsch | ||
| 30.07. | Guggenheim cuts Phathom Pharmaceuticals price target on guidance reduction | 2 | Investing.com | ||
| 30.07. | Phathom Pharmaceuticals, Inc. (PHAT) Reports Break-Even Earnings for Q2 | 4 | Zacks | ||
| 30.07. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 30.07. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.07. | Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 | 4 | GlobeNewswire (USA) | ||
| PHATHOM PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.06. | Phathom Pharmaceuticals schließt Rekrutierung für Phase-2-Studie zu EoE ab | 1 | Investing.com Deutsch | ||
| 23.06. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | H.C. Wainwright reiterates Buy on Phathom stock, $26 target | 1 | Investing.com | ||
| 21.05. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.05. | Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 01.05. | Earnings call transcript: Phathom Pharmaceuticals übertrifft EPS-Erwartungen für Q1 2026 | 7 | Investing.com Deutsch | ||
| 01.05. | Phathom Pharmaceuticals to Highlight VOQUEZNA (vonoprazan) at DDW 2026 Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 30.04. | Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 | 1 | Seeking Alpha | ||
| 30.04. | Phathom Q1 2026 slides: revenue doubles, profitability in sight | 4 | Investing.com | ||
| 30.04. | Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript | 4 | Benzinga.com | ||
| 30.04. | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | 540 | GlobeNewswire (Europe) | ~1.35 million total VOQUEZNA prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2... ► Artikel lesen | |
| 30.04. | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.04. | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| KUROS BIOSCIENCES | 23,020 | +2,22 % | Kuros Biosciences' MagnetOs: Revolution im Kampf gegen Knochendefekte | ||
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Breaking News! NurExone Biologic plant großes Börsen-Upgrade! | ||
| ABIVAX | 97,45 | -0,31 % | Abivax-Aktie: Zulassungsantrag rückt näher - Übernahme auch? | Die Abivax-Aktie steht vor einer entscheidenden Phase: Nach starken Phase-3-Daten, konstruktivem FDA-Feedback und einer prall gefüllten Kasse rückt der geplante Zulassungsantrag für Obefazimod in den... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,660 | +1,20 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| MICROBOT MEDICAL | 1,285 | +0,78 % | Microbot Medical Inc.: Microbot Medical Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter | Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,840 | +4,02 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| ARGENX | 887,20 | +0,05 % | DEUTSCHE BANK RESEARCH stuft Argenx auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Argenx von 900 auf 925 Euro angehoben, die auf Rekordniveau befindlichen Aktien aber von "Buy" auf "Hold" abgestuft. Es sei... ► Artikel lesen |
PHATHOM PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 9,180 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHATHOM PHARMACEUTICALS INC finden Sie auf Wallstreet Online.